Search
Non-Small Cell Lung Cancer Paid Clinical Trials in Massachusetts
A listing of 65 Non-Small Cell Lung Cancer clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 65 of 65
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Non-Small Cell Lung Cancer
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
The state of Massachusetts currently has 65 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Recruiting
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/12/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
Recruiting
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-sma... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/29/2024
Locations: Beverly Hospital, Beverly, Massachusetts +24 locations
Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation
Recruiting
This is a phase I/IIa, open-label, dose-escalation and expansion study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of H002 when given orally in patients with active EGFR mutation locally advanced or metastatic non-small cell lung cancer (NSCLC).
The study will contain two parts: Part A is dose escalation phase (i.e., Phase I) and Part B is dose expansion phase (i.e., Phase IIa).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Non-small Cell Lung Cancer
Immune and Genomic Markers in ALK+ NSCLC
Recruiting
The purpose of this research study is to obtain and study clinical history, and tissue and saliva specimens if available from participants with Anaplastic Lymphoma Kinase-ALK+ Non-Small Lung Cancer(NSCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/15/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Anaplastic Lymphoma Kinase Gene Translocation, Non-Small Cell Lung Cancer
Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
Recruiting
The goal of this prospective study to investigate the use of circulating tumor DNA (ctDNA) to guide end of therapy decisions in patients with melanoma or non-small-cell lung cancer.
The main question it aims to answer is:
• Do patients with metastatic melanoma or non-small-cell lung cancer, who have received at least 12 months of immune checkpoint inhibition (monotherapy or in combination) with evidence of disease response/control on imaging and have no evidence of circulating tumor DNA, have... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Melanoma, Non-small Cell Lung Cancer
61 - 65 of 65